JOHNSON & JOHNSON - FORM 8-K - EX-99.2O

Attached files

file	filename
8-K - JOHNSON & JOHNSON	a2q20128kcover.htm
EX-99.15 - JOHNSON & JOHNSON	a2q20128kexhibit9915.htm

Exhibit 99.2O



Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	SECOND QUARTER

	2012				2011				Percent
				Percent				Percent	Increase
	Amount			to Sales	Amount			to Sales	(Decrease)
Sales to customers	$	16,475		100.0	$	16,597		100.0	(0.7	)
Cost of products sold	5,143			31.2	5,172			31.2	(0.6	)
Selling, marketing and administrative expenses	4,965			30.1	5,215			31.4	(4.8	)
Research and development expense	1,766			10.7	1,882			11.3	(6.2	)
In-process research and development	429			2.6	—			—
Interest (income) expense, net	129			0.8	111			0.7
Other (income) expense, net	2,008			12.2	206			1.3
Restructuring expense	—			—	589			3.5
Earnings before provision for taxes on income	2,035			12.4	3,422			20.6	(40.5	)
Provision for taxes on income	627			3.9	646			3.9	(2.9	)
Net earnings	$	1,408		8.5	$	2,776		16.7	(49.3	)

Net earnings per share (Diluted)	$	0.50			$	1.00			(50.0	)

Average shares outstanding (Diluted)	2,798.2				2,781.3

Effective tax rate	30.8		%		18.9		%

Adjusted earnings before provision for taxes and net earnings ^{(1) (A)}
Earnings before provision for taxes on income	$	4,646		28.2	$	4,413		26.6	5.3
Net earnings	$	3,644		22.1	$	3,548		21.4	2.7
Net earnings per share (Diluted)	$	1.30			$	1.28			1.6
Effective tax rate	21.6		%		19.6		%

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.
^(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses the performance of the Company. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.



Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	SIX MONTHS

	2012				2011				Percent
				Percent				Percent	Increase
	Amount			to Sales	Amount			to Sales	(Decrease)
Sales to customers	$	32,614		100.0	$	32,770		100.0	(0.5	)
Cost of products sold	10,058			30.8	9,950			30.4	1.1
Selling, marketing and administrative expenses	9,980			30.6	10,271			31.3	(2.8	)
Research and development expense	3,411			10.5	3,620			11.0	(5.8	)
In-process research and development	429			1.3	—			—
Interest (income) expense, net	259			0.8	215			0.7
Other (income) expense, net	1,397			4.3	193			0.6
Restructuring expense	—			—	589			1.8
Earnings before provision for taxes on income	7,080			21.7	7,932			24.2	(10.7	)
Provision for taxes on income	1,762			5.4	1,680			5.1	4.9
Net earnings	$	5,318		16.3	$	6,252		19.1	(14.9	)

Net earnings per share (Diluted)	$	1.91			$	2.25			(15.1	)

Average shares outstanding (Diluted)	2,792.4				2,778.1

Effective tax rate	24.9		%		21.2		%

Adjusted earnings before provision for taxes and net earnings ^{(1) (A)}
Earnings before provision for taxes on income	$	9,574		29.4	$	9,269		28.3	3.3
Net earnings	$	7,448		22.8	$	7,295		22.3	2.1
Net earnings per share (Diluted)	$	2.67			$	2.63			1.5
Effective tax rate	22.2		%		21.3		%

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.
^(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses the performance of the Company. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	SECOND QUARTER
				Percent Change
	2012		2011	Total			Operations		Currency
Sales to customers by
segment of business

Consumer
U.S.	$	1,313	1,339	(1.9	)	%	(1.9	)	—
International	2,306		2,454	(6.0	)		2.0		(8.0	)
	3,619		3,793	(4.6	)		0.6		(5.2	)

Pharmaceutical
U.S.	3,094		3,239	(4.5	)		(4.5	)	—
International	3,197		2,994	6.8			15.5		(8.7	)
	6,291		6,233	0.9			5.1		(4.2	)

Med Devices & Diagnostics
U.S.	2,953		2,869	2.9			2.9		—
International	3,612		3,702	(2.4	)		3.8		(6.2	)
	6,565		6,571	(0.1	)		3.4		(3.5	)

U.S.	7,360		7,447	(1.2	)		(1.2	)	—
International	9,115		9,150	(0.4	)		7.1		(7.5	)
Worldwide	$	16,475	16,597	(0.7	)	%	3.5		(4.2	)



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	SIX MONTHS
				Percent Change
	2012		2011	Total			Operations		Currency
Sales to customers by
segment of business

Consumer
U.S.	$	2,629	2,684	(2.0	)	%	(2.0	)	—
International	4,585		4,791	(4.3	)		1.2		(5.5	)
	7,214		7,475	(3.5	)		—		(3.5	)

Pharmaceutical
U.S.	6,120		6,630	(7.7	)		(7.7	)	—
International	6,304		5,662	11.3			17.3		(6.0	)
	12,424		12,292	1.1			3.9		(2.8	)

Med Devices & Diagnostics
U.S.	5,830		5,741	1.6			1.6		—
International	7,146		7,262	(1.6	)		2.2		(3.8	)
	12,976		13,003	(0.2	)		1.9		(2.1	)

U.S.	14,579		15,055	(3.2	)		(3.2	)	—
International	18,035		17,715	1.8			6.8		(5.0	)
Worldwide	$	32,614	32,770	(0.5	)	%	2.2		(2.7	)



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	SECOND QUARTER
				Percent Change
	2012		2011	Total			Operations		Currency
Sales to customers by
geographic area

U.S.	$	7,360	7,447	(1.2	)	%	(1.2	)	—

Europe	4,165		4,543	(8.3	)		1.6		(9.9	)
Western Hemisphere excluding U.S.	1,728		1,543	12.0			22.4		(10.4	)
Asia-Pacific, Africa	3,222		3,064	5.2			7.7		(2.5	)
International	9,115		9,150	(0.4	)		7.1		(7.5	)

Worldwide	$	16,475	16,597	(0.7	)	%	3.5		(4.2	)



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	SIX MONTHS
				Percent Change
	2012		2011	Total			Operations		Currency
Sales to customers by
geographic area

U.S.	$	14,579	15,055	(3.2	)	%	(3.2	)	—

Europe	8,359		8,726	(4.2	)		2.9		(7.1	)
Western Hemisphere excluding U.S.	3,442		2,979	15.5			22.7		(7.2	)
Asia-Pacific, Africa	6,234		6,010	3.7			4.5		(0.8	)
International	18,035		17,715	1.8			6.8		(5.0	)

Worldwide	$	32,614	32,770	(0.5	)	%	2.2		(2.7	)



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

	Second Quarter				% Incr. /
(Dollars in Millions Except Per Share Data)	2012		2011		(Decr.)

Earnings before provision for taxes on income - as reported	$	2,035	3,422		(40.5	)	%

Intangible asset write-downs	939		—

Net litigation	669		315

Synthes integration/transaction costs and currency related	574		(102	)

In-process research and development	429		—

Restructuring - Cordis	—		676

DePuy ASR™ Hip related costs	—		102

Earnings before provision for taxes on income - as adjusted	$	4,646	4,413		5.3		%

Net Earnings - as reported	$	1,408	2,776		(49.3	)	%

Intangible asset write-downs	717		—

Net litigation	611		242

Synthes integration/transaction costs and currency related	564		(102	)

In-process research and development	344		—

Restructuring - Cordis	—		549

DePuy ASR™ Hip related costs	—		83

Net Earnings - as adjusted	$	3,644	3,548		2.7		%

Diluted Net Earnings per share - as reported	$	0.50	1.00		(50.0	)	%

Intangible asset write-downs	0.26		—

Net litigation	0.22		0.09

Synthes integration/transaction costs and currency related	0.20		(0.04	)

In-process research and development	0.12		—

Restructuring - Cordis	—		0.20

DePuy ASR™ Hip related costs	—		0.03

Diluted Net Earnings per share - as adjusted	$	1.30	1.28		1.6		%

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

	Six Months YTD					% Incr. /
(Dollars in Millions Except Per Share Data)	2012		2011			(Decr.)

Earnings before provision for taxes on income - as reported	$	7,080	$	7,932		(10.7	)	%

Intangible asset write-downs	939		—

Net litigation	669		576

Synthes integration/transaction costs and currency related	457		(102		)

In-process research and development	429		—

Restructuring - Cordis	—		676

DePuy ASR™ Hip related costs	—		187

Earnings before provision for taxes on income - as adjusted	$	9,574	9,269			3.3		%

Net Earnings - as reported	$	5,318	6,252			(14.9	)	%

Intangible asset write-downs	717		—

Net litigation	611		444

Synthes integration/transaction costs and currency related	458		(102		)

In-process research and development	344		—

Restructuring - Cordis	—		549

DePuy ASR™ Hip related costs	—		152

Net Earnings - as adjusted	$	7,448	7,295			2.1		%

Diluted Net Earnings per share - as reported	$	1.91	2.25			(15.1	)	%

Intangible asset write-downs	0.26		—

Net litigation	0.22		0.16

Synthes integration/transaction costs and currency related	0.16		(0.04		)

In-process research and development	0.12		—

Restructuring - Cordis	—		0.20

DePuy ASR™ Hip related costs	—		0.06

Diluted Net Earnings per share - as adjusted	$	2.67	2.63			1.5		%

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SECOND QUARTER
				% Change
		2012	2011	Reported		Operational⁽¹⁾		Currency
CONSUMER SEGMENT⁽²⁾

BABY CARE
US	$	106	105	1.0	%	1.0	%	—	%
Intl		472	493	(4.3	)	3.5		(7.8	)
WW		578	598	(3.3	)	3.2		(6.5	)

ORAL CARE
US		159	158	0.6		0.6		—
Intl		249	241	3.3		11.9		(8.6	)
WW		408	399	2.3		7.5		(5.2	)

OTC/NUTRITIONALS
US		336	330	1.8		1.8		—
Intl		696	753	(7.6	)	0.1		(7.7	)
WW		1,032	1,083	(4.7	)	0.6		(5.3	)

SKIN CARE
US		471	449	4.9		4.9		—
Intl		442	480	(7.9	)	(0.3	)	(7.6	)
WW		913	929	(1.7	)	2.2		(3.9	)

WOMEN'S HEALTH
US		80	121	(33.9	)	(33.9	)	—
Intl		322	356	(9.6	)	(0.2	)	(9.4	)
WW		402	477	(15.7	)	(8.7	)	(7.0	)

WOUND CARE/OTHER
US		161	176	(8.5	)	(8.5	)	—
Intl		125	131	(4.6	)	2.8		(7.4	)
WW		286	307	(6.8	)	(3.7	)	(3.1	)

TOTAL CONSUMER
US		1,313	1,339	(1.9	)	(1.9	)	—
Intl		2,306	2,454	(6.0	)	2.0		(8.0	)
WW	$	3,619	3,793	(4.6	)%	0.6	%	(5.2	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SECOND QUARTER
				% Change
		2012	2011	Reported		Operational⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4)}

IMMUNOLOGY
US	$	1,471	1,524	(3.5	)%	(3.5	)%	—	%
Intl		448	131	*		*		(8.1	)
WW		1,919	1,655	16.0		18.2		(2.2	)
REMICADE
US		890	836	6.5		6.5		—
US Exports⁽³⁾		366	527	(30.6	)	(30.6	)	—
Intl		267	8	*		*		(8.3	)
WW		1,523	1,371	11.1		12.7		(1.6	)
SIMPONI
US		63	61	3.3		3.3		—
Intl		62	6	*		*		(5.8	)
WW		125	67	86.6		89.5		(2.9	)
STELARA
US		152	100	52.0		52.0		—
Intl		96	76	26.3		35.1		(8.8	)
WW		248	176	40.9		45.7		(4.8	)
OTHER IMMUNOLOGY
US		—	—	—		—		—
Intl		23	41	(43.9	)	(39.2	)	(4.7	)
WW		23	41	(43.9	)	(39.2	)	(4.7	)

INFECTIOUS DISEASES
US		237	351	(32.5	)	(32.5	)	—
Intl		551	477	15.5		26.0		(10.5	)
WW		788	828	(4.8	)	1.3		(6.1	)
INTELENCE
US		42	38	10.5		10.5		—
Intl		49	41	19.5		30.4		(10.9	)
WW		91	79	15.2		20.8		(5.6	)
LEVAQUIN/FLOXIN
US		7	149	(95.3	)	(95.3	)	—
Intl		9	10	(10.0	)	(2.7	)	(7.3	)
WW		16	159	(89.9	)	(89.4	)	(0.5	)
PREZISTA
US		166	128	29.7		29.7		—
Intl		207	185	11.9		22.6		(10.7	)
WW		373	313	19.2		25.5		(6.3	)
OTHER INFECTIOUS DISEASES
US		22	36	(38.9	)	(38.9	)	—
Intl		286	241	18.7		29.1		(10.4	)
WW		308	277	11.2		20.2		(9.0	)

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SECOND QUARTER
				% Change
		2012	2011	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

NEUROSCIENCE
US	$	658	684	(3.8	)%	(3.8	)%	—	%
Intl		1,056	1,096	(3.6	)	3.2		(6.8	)
WW		1,714	1,780	(3.7	)	0.5		(4.2	)
CONCERTA/METHYLPHENIDATE
US		146	234	(37.6	)	(37.6	)	—
Intl		122	115	6.1		14.0		(7.9	)
WW		268	349	(23.2	)	(20.6	)	(2.6	)
INVEGA
US		76	76	0.0		0.0		—
Intl		66	52	26.9		33.6		(6.7	)
WW		142	128	10.9		13.6		(2.7	)
INVEGA SUSTENNA/XEPLION
US		120	70	71.4		71.4		—
Intl		75	7	*		*		(8.8	)
WW		195	77	*		*		(3.4	)
RISPERDAL CONSTA
US		110	110	0.0		0.0		—
Intl		245	294	(16.7	)	(9.3	)	(7.4	)
WW		355	404	(12.1	)	(6.7	)	(5.4	)
OTHER NEUROSCIENCE
US		206	194	6.2		6.2		—
Intl		548	628	(12.7	)	(7.3	)	(5.4	)
WW		754	822	(8.3	)	(4.2	)	(4.1	)

ONCOLOGY
US		119	93	28.0		28.0		—
Intl		467	459	1.7		11.2		(9.5	)
WW		586	552	6.2		14.1		(7.9	)
DOXIL/CAELYX
US		6	56	(89.3	)	(89.3	)	—
Intl		7	82	(91.5	)	(89.9	)	(1.6	)
WW		13	138	(90.6	)	(89.7	)	(0.9	)
VELCADE
US		—	—	—		—		—
Intl		318	347	(8.4	)	(0.1	)	(8.3	)
WW		318	347	(8.4	)	(0.1	)	(8.3	)
ZYTIGA
US		113	37	*		*		—
Intl		119	12	*		*		(10.0	)
WW		232	49	*		*		(5.1	)
OTHER ONCOLOGY
US		—	—	—		—		—
Intl		23	18	27.8		36.4		(8.6	)
WW		23	18	27.8		36.4		(8.6	)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SECOND QUARTER
				% Change
		2012	2011	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

TOTAL OTHER
US	$	609	587	3.7	%	3.7	%	—	%
Intl		675	831	(18.8	)	(11.8	)	(7.0	)
WW		1,284	1,418	(9.4	)	(5.3	)	(4.1	)
ACIPHEX/PARIET
US		104	101	3.0		3.0		—
Intl		128	146	(12.3	)	(2.8	)	(9.5	)
WW		232	247	(6.1	)	(0.5	)	(5.6	)
PROCRIT/EPREX
US		232	257	(9.7	)	(9.7	)	—
Intl		169	218	(22.5	)	(14.9	)	(7.6	)
WW		401	475	(15.6	)	(12.1	)	(3.5	)
OTHER
US		273	229	19.2		19.2		—
Intl		378	467	(19.1	)	(13.2	)	(5.9	)
WW		651	696	(6.5	)	(2.6	)	(3.9	)

TOTAL PHARMACEUTICAL
US		3,094	3,239	(4.5	)	(4.5	)	—
Intl		3,197	2,994	6.8		15.5		(8.7	)
WW	$	6,291	6,233	0.9	%	5.1	%	(4.2	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SECOND QUARTER
				% Change
		2012	2011	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES AND DIAGNOSTICS ^{(2) (4)}

CARDIOVASCULAR CARE
US	$	195	210	(7.1	)%	(7.1	)%	—	%
Intl		309	377	(18.0	)	(13.1	)	(4.9	)
WW		504	587	(14.1	)	(10.9	)	(3.2	)

DIABETES CARE
US		337	333	1.2		1.2		—
Intl		336	348	(3.4	)	4.6		(8.0	)
WW		673	681	(1.2	)	2.9		(4.1	)

DIAGNOSTICS
US		258	281	(8.2	)	(8.2	)	—
Intl		256	269	(4.8	)	0.8		(5.6	)
WW		514	550	(6.5	)	(3.8	)	(2.7	)

GENERAL SURGERY
US		602	621	(3.1	)	(3.1	)	—
Intl		1,038	1,079	(3.8	)	3.1		(6.9	)
WW		1,640	1,700	(3.5	)	0.9		(4.4	)

INFECTION PREVENTION/OTHER
US		99	98	1.0		1.0		—
Intl		131	134	(2.2	)	3.3		(5.5	)
WW		230	232	(0.9	)	2.3		(3.2	)

ORTHOPAEDICS
US		873	770	13.4		13.4		—
Intl		755	699	8.0		14.8		(6.8	)
WW		1,628	1,469	10.8		14.0		(3.2	)

SPECIALTY SURGERY
US		336	311	8.0		8.0		—
Intl		310	309	0.3		7.6		(7.3	)
WW		646	620	4.2		7.8		(3.6	)

VISION CARE
US		253	245	3.3		3.3		—
Intl		477	487	(2.1	)	1.2		(3.3	)
WW		730	732	(0.3	)	1.9		(2.2	)

TOTAL MEDICAL DEVICES AND DIAGNOSTICS
US		2,953	2,869	2.9		2.9		—
Intl		3,612	3,702	(2.4	)	3.8		(6.2	)
WW	$	6,565	6,571	(0.1	)%	3.4	%	(3.5	)%
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SIX MONTHS
				% Change
		2012	2011	Reported		Operational⁽¹⁾		Currency
CONSUMER SEGMENT⁽²⁾

BABY CARE
US	$	205	210	(2.4	)%	(2.4	)%	—	%
Intl		913	949	(3.8	)	1.7		(5.5	)
WW		1,118	1,159	(3.5	)	1.0		(4.5	)

ORAL CARE
US		314	321	(2.2	)	(2.2	)	—
Intl		481	469	2.6		8.5		(5.9	)
WW		795	790	0.6		4.1		(3.5	)

OTC/NUTRITIONALS
US		717	727	(1.4	)	(1.4	)	—
Intl		1,419	1,485	(4.4	)	0.9		(5.3	)
WW		2,136	2,212	(3.4	)	0.2		(3.6	)

SKIN CARE
US		924	875	5.6		5.6		—
Intl		896	953	(6.0	)	(1.0	)	(5.0	)
WW		1,820	1,828	(0.4	)	2.2		(2.6	)

WOMEN'S HEALTH
US		173	246	(29.7	)	(29.7	)	—
Intl		638	690	(7.5	)	(0.8	)	(6.7	)
WW		811	936	(13.4	)	(8.5	)	(4.9	)

WOUND CARE/OTHER
US		296	305	(3.0	)	(3.0	)	—
Intl		238	245	(2.9	)	2.3		(5.2	)
WW		534	550	(2.9	)	(0.6	)	(2.3	)

TOTAL CONSUMER
US		2,629	2,684	(2.0	)	(2.0	)	—
Intl		4,585	4,791	(4.3	)	1.2		(5.5	)
WW	$	7,214	7,475	(3.5	)%	0.0%		(3.5	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SIX MONTHS
				% Change
		2012	2011	Reported		Operational⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4)}

IMMUNOLOGY
US	$	2,924	2,960	(1.2	)%	(1.2	)%	—	%
Intl		890	275	*		*		(5.2	)
WW		3,814	3,235	17.9		19.1		(1.2	)
REMICADE
US		1,772	1,624	9.1		9.1		—
US Exports⁽³⁾		744	1,017	(26.8	)	(26.8	)	—
Intl		528	15	*		*		(5.3	)
WW		3,044	2,656	14.6		15.6		(1.0	)
SIMPONI
US		127	114	11.4		11.4		—
Intl		114	48	*		*		(8.6	)
WW		241	162	48.8		51.3		(2.5	)
STELARA
US		281	205	37.1		37.1		—
Intl		188	137	37.2		45.5		(8.3	)
WW		469	342	37.1		40.4		(3.3	)
OTHER IMMUNOLOGY
US		—	—	—		—		—
Intl		60	75	(20.0	)	(16.6	)	(3.4	)
WW		60	75	(20.0	)	(16.6	)	(3.4	)

INFECTIOUS DISEASES
US		479	975	(50.9	)	(50.9	)	—
Intl		1,064	784	35.7		44.3		(8.6	)
WW		1,543	1,759	(12.3	)	(8.5	)	(3.8	)
INTELENCE
US		85	76	11.8		11.8		—
Intl		86	72	19.4		27.4		(8.0	)
WW		171	148	15.5		19.4		(3.9	)
LEVAQUIN/FLOXIN
US		25	571	(95.6	)	(95.6	)	—
Intl		20	22	(9.1	)	(3.9	)	(5.2	)
WW		45	593	(92.4	)	(92.2	)	(0.2	)
PREZISTA
US		326	254	28.3		28.3		—
Intl		371	325	14.2		22.2		(8.0	)
WW		697	579	20.4		24.9		(4.5	)
OTHER INFECTIOUS DISEASES
US		43	74	(41.9	)	(41.9	)	—
Intl		587	365	60.8		70.3		(9.5	)
WW		630	439	43.5		51.4		(7.9	)

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SIX MONTHS
				% Change
		2012	2011	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

NEUROSCIENCE
US	$	1,332	1,372	(2.9	)%	(2.9	)%	—	%
Intl		2,029	2,153	(5.8	)	(1.3	)	(4.5	)
WW		3,361	3,525	(4.7	)	(1.9	)	(2.8	)
CONCERTA/METHYLPHENIDATE
US		343	488	(29.7	)	(29.7	)	—
Intl		233	223	4.5		10.1		(5.6	)
WW		576	711	(19.0	)	(17.2	)	(1.8	)
INVEGA
US		145	145	0.0		0.0		—
Intl		118	103	14.6		18.8		(4.2	)
WW		263	248	6.0		7.8		(1.8	)
INVEGA SUSTENNA/XEPLION
US		220	135	63.0		63.0		—
Intl		136	7	*		*		(6.2	)
WW		356	142	*		*		(2.4	)
RISPERDAL CONSTA
US		223	224	(0.4	)	(0.4	)	—
Intl		493	584	(15.6	)	(10.5	)	(5.1	)
WW		716	808	(11.4	)	(7.7	)	(3.7	)
OTHER NEUROSCIENCE
US		401	380	5.5		5.5		—
Intl		1,049	1,236	(15.1	)	(11.7	)	(3.4	)
WW		1,450	1,616	(10.3	)	(7.7	)	(2.6	)

ONCOLOGY
US		226	157	43.9		43.9		—
Intl		956	834	14.6		21.8		(7.2	)
WW		1,182	991	19.3		25.3		(6.0	)
DOXIL/CAELYX
US		13	120	(89.2	)	(89.2	)	—
Intl		24	157	(84.7	)	(83.4	)	(1.3	)
WW		37	277	(86.6	)	(85.9	)	(0.7	)
VELCADE
US		—	—	—		—		—
Intl		671	627	7.0		13.4		(6.4	)
WW		671	627	7.0		13.4		(6.4	)
ZYTIGA
US		213	37	*		*		—
Intl		219	17	*		*		(7.1	)
WW		432	54	*		*		(3.6	)
OTHER ONCOLOGY
US		—	—	—		—		—
Intl		42	33	27.3		33.2		(5.9	)
WW		42	33	27.3		33.2		(5.9	)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SIX MONTHS
				% Change
		2012	2011	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

TOTAL OTHER
US	$	1,159	1,166	(0.6	)%	(0.6	)%	—	%
Intl		1,365	1,616	(15.5	)	(10.9	)	(4.6	)
WW		2,524	2,782	(9.3	)	(6.6	)	(2.7	)
ACIPHEX/PARIET
US		200	210	(4.8	)	(4.8	)	—
Intl		254	276	(8.0	)	(1.5	)	(6.5	)
WW		454	486	(6.6	)	(2.9	)	(3.7	)
PROCRIT/EPREX
US		436	447	(2.5	)	(2.5	)	—
Intl		341	425	(19.8	)	(14.5	)	(5.3	)
WW		777	872	(10.9	)	(8.3	)	(2.6	)
OTHER
US		523	509	2.8		2.8		—
Intl		770	915	(15.8	)	(12.1	)	(3.7	)
WW		1,293	1,424	(9.2	)	(6.8	)	(2.4	)

TOTAL PHARMACEUTICAL
US		6,120	6,630	(7.7	)	(7.7	)	—
Intl		6,304	5,662	11.3		17.3		(6.0	)
WW	$	12,424	12,292	1.1	%	3.9	%	(2.8	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SIX MONTHS
				% Change
		2012	2011	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES AND DIAGNOSTICS ^{(2) (4)}

CARDIOVASCULAR CARE
US	$	371	452	(17.9	)%	(17.9	)%	—	%
Intl		615	770	(20.1	)	(17.2	)	(2.9	)
WW		986	1,222	(19.3	)	(17.5	)	(1.8	)
DIABETES CARE
US		689	644	7.0		7.0		—
Intl		654	674	(3.0	)	2.5		(5.5	)
WW		1,343	1,318	1.9		4.7		(2.8	)
DIAGNOSTICS
US		511	546	(6.4	)	(6.4	)	—
Intl		515	525	(1.9	)	1.6		(3.5	)
WW		1,026	1,071	(4.2	)	(2.5	)	(1.7	)
GENERAL SURGERY
US		1,195	1,217	(1.8	)	(1.8	)	—
Intl		2,070	2,104	(1.6	)	2.8		(4.4	)
WW		3,265	3,321	(1.7	)	1.1		(2.8	)
INFECTION PREVENTION/OTHER
US		215	193	11.4		11.4		—
Intl		259	255	1.6		4.8		(3.2	)
WW		474	448	5.8		7.6		(1.8	)
ORTHOPAEDICS
US		1,656	1,581	4.7		4.7		—
Intl		1,465	1,391	5.3		9.5		(4.2	)
WW		3,121	2,972	5.0		6.9		(1.9	)
SPECIALTY SURGERY
US		663	607	9.2		9.2		—
Intl		611	590	3.6		8.4		(4.8	)
WW		1,274	1,197	6.4		8.8		(2.4	)
VISION CARE
US		530	501	5.8		5.8		—
Intl		957	953	0.4		1.9		(1.5	)
WW		1,487	1,454	2.3		3.3		(1.0	)

TOTAL MEDICAL DEVICES AND DIAGNOSTICS
US		5,830	5,741	1.6		1.6		—
Intl		7,146	7,262	(1.6	)	2.2		(3.8	)
WW	$	12,976	13,003	(0.2	)%	1.9	%	(2.1	)%
*Percentage greater than 100%
⁽¹⁾Operational growth excludes the effect of currency
⁽²⁾ Select areas (unaudited)
⁽³⁾Reported as U.S. sales
⁽⁴⁾Prior year amounts have been reclassified to conform to current year product disclosure

Attached files

Stock widget

Investing forum

JOHNSON & JOHNSON Reports

JOHNSON & JOHNSON - FORM 8-K - EX-99.2O - July 17, 2012

Attached files

Stock widget

Investing forum

JOHNSON & JOHNSON Reports